- Home
- LUMO vs ACHL Comparison
LUMO vs ACHL Comparison
Compare LUMO & ACHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUMO
- ACHL
- Stock Information
- Founded
- LUMO 2011
- ACHL 2016
- Country
- LUMO United States
- ACHL United Kingdom
- Employees
- LUMO N/A
- ACHL N/A
- Industry
- LUMO Biotechnology: Pharmaceutical Preparations
- ACHL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LUMO Health Care
- ACHL Health Care
- Exchange
- LUMO Nasdaq
- ACHL Nasdaq
- Market Cap
- LUMO 37.4M
- ACHL 43.6M
- IPO Year
- LUMO N/A
- ACHL 2021
- Fundamental
- Price
- LUMO $4.34
- ACHL $0.95
- Analyst Decision
- LUMO Buy
- ACHL Buy
- Analyst Count
- LUMO 4
- ACHL 2
- Target Price
- LUMO $9.38
- ACHL $4.00
- AVG Volume (30 Days)
- LUMO 133.0K
- ACHL 107.8K
- Earning Date
- LUMO 11-07-2024
- ACHL 11-14-2024
- Dividend Yield
- LUMO N/A
- ACHL N/A
- EPS Growth
- LUMO N/A
- ACHL N/A
- EPS
- LUMO N/A
- ACHL N/A
- Revenue
- LUMO $2,205,000.00
- ACHL N/A
- Revenue This Year
- LUMO $184.11
- ACHL N/A
- Revenue Next Year
- LUMO N/A
- ACHL N/A
- P/E Ratio
- LUMO N/A
- ACHL N/A
- Revenue Growth
- LUMO 26.94
- ACHL N/A
- 52 Week Low
- LUMO $1.37
- ACHL $0.63
- 52 Week High
- LUMO $4.58
- ACHL $1.76
- Technical
- Relative Strength Index (RSI)
- LUMO 4.26
- ACHL 29.24
- Support Level
- LUMO $4.31
- ACHL $0.97
- Resistance Level
- LUMO $4.39
- ACHL $1.01
- Average True Range (ATR)
- LUMO 0.03
- ACHL 0.03
- MACD
- LUMO -0.44
- ACHL -0.01
- Stochastic Oscillator
- LUMO 0.00
- ACHL 0.87
About LUMO Lumos Pharma Inc.
Lumos Pharma Inc is a biopharmaceutical company that develops treatments for cancer and rare diseases. It carries out both clinical-stage and preclinical research on a range of molecules that help the immune system fight off cancer cells. The treatments are available orally and can be used in conjunction with other cancer therapies. The company also researches an Ebola vaccine. Lumos contracts with manufacturing organizations to make their treatments, engages in partnerships with pharmaceutical companies, and operates in the United States.
About ACHL Achilles Therapeutics plc
Achilles Therapeutics PLC is a biopharmaceutical company. It is developing AI-powered precision T-cell therapies targeting clonal neoantigens to treat solid tumors. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.